{"id":"NCT02551874","sponsor":"AstraZeneca","briefTitle":"A 24-week Open-Label, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects withType 2 Diabetes Who Have Glycemic Control on Metformin","officialTitle":"A 24-week International, Multicenter, Randomized, Open-Label, Active-Controlled, Parallel Group, Phase 3b Trial With a 28-week Extension to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin Compared to Insulin Glargine in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin With or Without Sulfonylurea Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-20","primaryCompletion":"2017-05-08","completion":"2017-11-10","firstPosted":"2015-09-16","resultsPosted":"2018-09-18","lastUpdate":"2018-12-11"},"enrollment":650,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Saxagliptin, Onglyza","otherNames":["Onglyza"]},{"type":"DRUG","name":"Dapagliflozin, Farxiga","otherNames":["BMS-512148"]},{"type":"DRUG","name":"Glargine insulin","otherNames":["Lantus"]},{"type":"DRUG","name":"Metformin","otherNames":["Glucophage"]}],"arms":[{"label":"Saxagliptin/Dapagliflozin/Metformin","type":"EXPERIMENTAL"},{"label":"Insulin Glargine, Lantos/Metformin","type":"ACTIVE_COMPARATOR"}],"summary":"This research study of subjects with inadequately controlled type 2 diabetes mellitus (T2DM) will compare the glycemic control (measured by HbA1c) in subjects co-administered saxagliptin and dapagliflozin, in addition to metformin with or without sulfonylurea, to subjects receiving insulin glargine, in addition to metformin with or without sulfonylurea, over a treatment period of 52 weeks.","primaryOutcome":{"measure":"Mean Change From Baseline in HbA1c at Week 24","timeFrame":"Baseline and Week 24","effectByArm":[{"arm":"Dapagliflozin + Saxagliptin + Metformin","deltaMin":-1.67,"sd":null},{"arm":"Titrated Insulin + Metformin","deltaMin":-1.54,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.118"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":40,"countries":["United States","Czechia","Denmark","Hungary","Mexico","Poland","Romania","South Africa","Spain","Sweden"]},"refs":{"pmids":["31167892"],"seeAlso":["http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4129&filename=cv181-369_SAP_redacted.pdf","http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&studyid=4129&filename=cv181-369_CSP_redacted.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":324},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Headache","Influenza"]}}